Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Exclusion Criteria

• •Has uncontrolled or significant cardiovascular disease before randomization
• •Has clinically significant corneal disease
• •Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
• •Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
• •Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
• •Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
• •Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
• •Has known additional malignancy that is progressing or has required active treatment within the past 5 years
• •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease, or where suspected ILD/pneumonitis cannot be ruled out by standard diagnostic assessments
• •Has an active infection requiring systemic therapy
• •Has concurrent active HBV and HCV infection
• •Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness